Document:

Exhibit

            

Exhibit 10.2
THIRD AMENDMENT 
to the 
Dover Corporation 
Pension Replacement Plan  
(As Amended and Restated as of January 1, 2010)
WHEREAS, Dover Corporation (the “Corporation”) has heretofore adopted the Dover Corporation Pension Replacement Plan, as amended and restated as of January 1, 2010 (the “Plan”); and
WHEREAS, in connection with the spin off of Apergy Corporation and its subsidiaries to the shareholders of the Corporation, it is necessary to amend the Plan to facilitate certain actions contemplated under that certain Employee Matters Agreement dated May 9, 2018, between the Corporation and Apergy Corporation.
NOW, THEREFORE, by virtue and in exercise of the power granted to the Dover Corporation Benefits Committee (the "Benefits Committee") under Article 9 of the Plan, the Plan is hereby amended, effective as of the date below written, by adding the following new Appendix D to the Plan:
"APPENDIX D
D.1.1    For purposes of this Appendix D, the following terms shall have the meanings set forth below.  Terms not otherwise defined in this Appendix D shall have the meaning given such terms under the Plan.
a.    'Affected Employee' means those employees of Apergy Corporation, and its subsidiaries who, as of the Effective Time, are actively employed or on a leave of absence approved by Apergy Corporation or its subsidiaries and who as of such date have an accrued Retirement Benefit under the Plan.
b.    'Effective Time' has the meaning given such term under the Separation and Distribution Agreement between the Company and Apergy Corporation dated May 9, 2018.
D.1.2    Effective as of May 1, 2018, each Affected Employee's Additional Years of Service, Applicable Percentage, Final Average Compensation, Compensation, Social Security Integration Level, and Years of Service shall be frozen as of May 1, 2018, and each such Affected Employee's Retirement Benefit under the Plan shall be converted to an actuarially equivalent lump sum determined as though such Affected Employee had a Termination of Employment immediately prior to the Effective Time and using the actuarial assumptions for such purpose as set forth in the Plan; provided, however, that for purposes of determining his or her Retirement Benefit as described in this Section D.1.2 of this Appendix D, each Affected Employee's Years of Service will include the period May 1, 2018 through December 31, 2018.   
D.1.3    Following the determination of each Affected Employee's lump sum Retirement Benefit as set forth in Section D.1.2, the lump sum value shall be reduced by the amounts necessary to pay the employee portion of any Federal Insurance Contributions Act ('FICA') taxes payable with respect to the lump sum amount and any federal, state or local income taxes that become payable by an Affected Employee as a result of the reduction for FICA taxes as permitted under Treasury Regulation Section 1.409A-3(j)(4)(vii) using tax rate and other assumptions as determined by the Company.
D.1.4    As of the Effective Time, the liability for the value of the lump sum Retirement Benefit of each Affected Employee, as determined in accordance with Section D.1.3 of this Appendix D, shall be assumed by Apergy Corporation or one of its subsidiaries, and shall be administered in accordance with the Apergy Executive Deferred Compensation Plan and shall cease to be a liability of the Company."

            

IN WITNESS WHEREOF, the Benefits Committee has caused this amendment to be executed by its duly authorized member, this 8th day of May, 2018.
The Benefits Committee 

By:/s/ Jay L. KloosterboerEXECUTION
VERSION

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

ASSET
PURCHASE AGREEMENT

 

This
Asset Purchase Agreement (this “Agreement”), dated as of March 21, 2018, is entered into between Ascendance
Biotechnology, Inc., a Delaware corporation (the “Company”), and AgeX Therapeutics, Inc., a Delaware corporation
(“Buyer”).

 

RECITALS

 

WHEREAS,
the Company is primarily engaged in the business of developing, manufacturing and selling products and services using liver-related
cells or cell types, including stem cell derived hepatocytes, for research in support of clinical diagnostics, research, drug
development, biological modeling of disease or any other use related to the modeling, assessment or development of drugs, chemicals
or cosmetics, including the trade-named HepatoPac®, HepatoMune® or HepatoStemTM products;

 

WHEREAS,
the Company is also engaged in the business of developing, manufacturing and selling stem cells, products derived from stem cells
and products related to stem cell research and toxicological screenings under the [***] (the “Non-Liver Business”);
and

 

WHEREAS,
the Company wishes to sell and assign to Buyer, and Buyer wishes to purchase and assume from the Company, the rights and obligations
of the Company to the Purchased Assets and the Assumed Liabilities (as defined herein) related to the Non-Liver Business, subject
to the terms and conditions set forth herein.

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

    	 

    	 

    

 

Article
I

PURCHASE AND SALE

 

Section
1.01 Purchase and Sale of Assets. Subject to the terms and conditions set forth herein, the Company shall sell, assign, transfer,
convey and deliver to Buyer, and Buyer shall purchase from the Company, the Company’s right, title and interest in the following
assets (collectively, the “Purchased Assets”), free and clear of any mortgage, pledge, lien, charge, security
interest, claim or other encumbrance (“Encumbrance”) except to the extent disclosed in this Agreement or the
below referenced schedule attached hereto:

 

(a)
the inventory, finished goods, raw materials, work in progress, packaging, supplies and parts set forth on Schedule 1.01(a)
(collectively, “Inventory”);

 

(b)
the contracts set forth on Schedule 1.01(b) (collectively, “Assigned Contracts”);

 

(c)
the intellectual property set forth on Schedule 1.01(c) (“Purchased IP”);

 

(d)
the equipment, supplies and other tangible personal property of the Company set forth on Schedule 1.01(d);

 

(e)
all of the Company’s rights under warranties, indemnities, non-competition agreements, non-disclosure agreements, non-solicitation
agreements, exclusive relationships, and all similar rights against third parties to the extent exclusively related to the Purchased
Assets; and

 

(f)
the books and records, including books of account, ledgers and general, financial and accounting records, machinery and equipment
maintenance files, customer lists, customer purchasing histories, price lists, distribution lists, supplier lists, production
data, quality control records and procedures, customer complaints and inquiry files, research and development files, records and
data, sales material and records, strategic plans, internal financial statements and marketing and promotions surveys, material
and research, that exclusively relate to the Non-Liver Business or the Purchased Assets set forth on Schedule 1.01(f) (all
of which exclusively relate to the Non-Liver Business).

 

Section
1.02 Excluded Assets. Buyer expressly understands and agrees that, other than the Purchased Assets set forth in Section
1.01, Buyer is not purchasing or acquiring, and the Company is not selling or assigning, any other assets or properties of
the Company, and all such other assets and properties shall be excluded from the Purchased Assets (collectively, the “Excluded
Assets”).

 

Section
1.03 Assumption of Liabilities. Buyer assumes and agrees to pay, perform and discharge any liabilities and obligations arising
after the Closing (as defined herein) under the Purchased Assets (including the Assigned Contracts and/or Purchased IP, but only
(a) to the extent provided in (i) that [***], and (ii) the Assignment and Assumption Agreement referenced in Section 2.02(a)(ii)
with respect to all Assigned Contracts, and (b) to the extent that such liabilities and obligations do not relate to any breach,
default or violation by the Company on or prior to the Closing) (collectively, the “Assumed Liabilities”).
Other than the Assumed Liabilities, Buyer shall not assume any liabilities or obligations of the Company of any kind, whether
known or unknown, contingent, matured or otherwise, whether currently existing or hereinafter created (such liabilities, the “Retained
Liabilities”). Notwithstanding anything to the contrary herein, for the avoidance of doubt, any liabilities or obligations
of the Company to [***]resulting from any pre-Closing breach or non-fulfillment of any covenant, agreement or obligation by the
Company, and any obligation or liability of the Company to indemnify [***]with respect to any liability that arose or matter that
occurred prior to Closing, under the [***], shall constitute (a) “Assumed Liabilities” to the extent related to the
Non-Liver Business and (b) “Retained Liabilities,” to the extent not related to the Non-Liver Business.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 	2	 

    	 

    

 

Section
1.04 Purchase Price. The aggregate purchase price for the Purchased Assets and the agreement of the Company to execute and
deliver the License Agreement (as defined below), the BioTime and ReCyte Sublicense (as defined below) and the ESI Sublicense
(as defined below) shall be [***] (the “Purchase Price”), plus the assumption of the Assumed Liabilities. The
Buyer shall pay the Purchase Price to the Company at the Closing in cash, by wire transfer of immediately available funds in accordance
with the wire transfer instructions set forth on Schedule 1.04.

 

Section
1.05 Allocation of Purchase Price. The Company and Buyer agree to allocate the Purchase Price among the Purchased Assets for
all purposes (including tax and financial accounting) in accordance with Schedule 1.05. Buyer and the Company shall file
all tax returns (including amended returns and claims for refund) and information reports in a manner consistent with such allocation.

 

Section
1.06 Withholding Tax. Buyer shall be entitled to deduct and withhold from the Purchase Price all taxes that Buyer is required
to deduct and withhold under any applicable tax law. All such withheld amounts shall be treated as delivered to the Company hereunder.

 

Section
1.07 Third Party Consents. To the extent that the Company’s rights under any Assigned Contract, or any other Purchased
Asset, may not be assigned to Buyer without the consent of another person which has not been obtained, this Agreement shall not
constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and the
Company shall use its commercially reasonable efforts to obtain any such required consent(s) as promptly as possible. If any such
consent shall not be obtained or if any attempted assignment would be ineffective or would impair Buyer’s rights under the
Purchased Asset in question so that Buyer would not in effect acquire the benefit and burdens of all such rights, the Company
shall use its reasonable best efforts to act after the Closing as Buyer’s agent (at Buyer’s expense) in order to obtain
for it the benefits and burdens thereunder and shall reasonably cooperate with Buyer in any other reasonable arrangement designed
to provide such benefits and burdens to Buyer. Buyer agrees that the Company shall have not any liability whatsoever to Buyer
arising out of or relating to the failure to obtain any such consent or give any such notice, and no representation, warranty
or covenant of the Company herein shall be breached or deemed breached, and no condition shall be deemed not satisfied, as a result
of such failure or any suit, litigation, claim, action, arbitration, cease and desist letter or proceeding or investigation commenced
or threatened by or on behalf of any person arising out of or relating to the failure to obtain any such consent.

 

Article
II

CLOSING

 

Section
2.01 Closing. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take
place simultaneously with the execution of this Agreement on the date of this Agreement (the “Closing Date”)
at the offices of Duane Morris LLP, 30 South 17th Street, Philadelphia, Pennsylvania 19103, or at such other location, or electronically,
as the parties hereto may agree. The consummation of the transactions contemplated by this Agreement shall be deemed to occur
at 12:01 a.m. on the Closing Date.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 	3	 

    	 

    

 

Section
2.02 Closing Deliverables.

 

(a)
At the Closing, the Company shall deliver to Buyer the following:

 

(i)
a bill of sale in form and substance reasonably acceptable to Buyer (the “Bill of Sale”) and duly executed
by the Company, transferring the tangible personal property included in the Purchased Assets to Buyer;

 

(ii)
an assignment and assumption agreement in form and substance reasonably acceptable to Buyer (the “Assignment and Assumption
Agreement”) and duly executed by the Company, effecting the assignment to, and assumption by, Buyer of the Assigned
Contracts and other intangible assets included in the Purchased Assets (other than the Purchased IP) and the Assumed Liabilities;

 

(iii)
[***];

 

(iv)
an assignment and assumption agreement in form and substance reasonably acceptable to Buyer (the “Intellectual Property
Assignment”) and duly executed by the Company, transferring the Company’s right, title and interest in and to
the Purchased IP to Buyer;

 

(v)
the Patent License Agreement, dated March [__], 2018, by and between Buyer and the Company ( the “License Agreement”)
and duly executed by the Company;

 

(vi)
sublicense agreements in form and substance reasonably acceptable to Buyer and duly executed by the Company, sublicensing patent
rights and other rights pursuant to: (i) that certain License Agreement, dated November 24, 2015 as amended from time to time,
by and among BioTime, Inc., a California corporation, ReCyte Therapeutics, Inc., a California corporation, and the Company to
Buyer (such sublicense, the “BioTime and ReCyte Sublicense”); (ii) that certain License Agreement effective
as of November 24, 2015, as amended from time to time, by and between ESI and the Company to Buyer (such sublicense, the “ESI
Sublicense”); and (iii) that certain [***] ([***] and, together with the BioTime and ReCyte Sublicense and the ESI Sublicense,
collectively, the “Sublicenses”);

 

(vii)
copies of all consents, approvals, waivers and authorizations referred to in Section 3.02 of the disclosure schedules attached
hereto (“Disclosure Schedules”);

 

(viii)
a certificate pursuant to Treasury Regulations Section 1.1445-2(b) that the Company is not a foreign person within the meaning
of Section 1445 of the Internal Revenue Code duly executed by the Company;

 

(ix)
a certificate of the Secretary (or equivalent officer) of the Company certifying as to (A) the resolutions of the board of directors
of the Company, duly adopted and in effect, which authorize the execution, delivery and performance of this Agreement and the
transactions contemplated hereby, and (B) the names and signatures of the officers of the Company authorized to sign this Agreement
and the documents to be delivered hereunder; and

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 	4	 

    	 

    

 

(x)
such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory
to Buyer, as may be required to give effect to this Agreement.

 

(b)
At the Closing, Buyer shall deliver to the Company the following:

 

(i)
the Purchase Price;

 

(ii)
the Assignment and Assumption Agreement duly executed by Buyer;

 

(iii)
[***];

 

(iv)
the Bill of Sale duly executed by Buyer;

 

(v)
the Intellectual Property Assignment duly executed by Buyer;

 

(vi)
License Agreement duly executed by Buyer;

 

(vii)
the Sublicenses duly executed by Buyer;

 

(viii)
copies of all consents and authorizations referred to in Section 4.02 of the Disclosure Schedules;

 

(ix)
a certificate of the Secretary or Assistant Secretary (or equivalent officer) of Buyer certifying as to (A) the resolutions of
the board of directors of Buyer, duly adopted and in effect, which authorize the execution, delivery and performance of this Agreement
and the transactions contemplated hereby, and (B) the names and signatures of the officers of Buyer authorized to sign this Agreement
and the documents to be delivered hereunder; and

 

(x)
such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory
to the Company, as may be required to give effect to this Agreement.

 

Article
III

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The
Company represents and warrants to Buyer that the statements contained in this Article III are true and correct as of the
date hereof. For purposes of this Article III, “Company’s knowledge,” “knowledge of Company”
and any similar phrases shall mean the actual or constructive knowledge of any officer of the Company, after reasonable inquiry.

 

Section
3.01 Organization and Authority of the Company; Enforceability. The Company is a corporation duly organized, validly existing
and in good standing under the laws of the state of Delaware. The Company has full corporate power and authority to enter into
this Agreement and the documents to be delivered hereunder, to carry out its obligations hereunder and to consummate the transactions
contemplated hereby. The execution, delivery and performance by the Company of this Agreement and the documents to be delivered
hereunder and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action
on the part of the Company. This Agreement and the documents to be delivered by the Company hereunder have been duly executed
and delivered by the Company, and (assuming due authorization, execution and delivery by Buyer) this Agreement and the documents
to be delivered hereunder constitute legal, valid and binding obligations of the Company, enforceable against the Company in accordance
with their respective terms.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 	5	 

    	 

    

 

Section
3.02 No Conflicts; Consents. Except as set forth in Section 3.02 of the Disclosure Schedules, execution, delivery and
performance by the Company of this Agreement and the documents to be delivered by the Company hereunder, and the consummation
of the transactions contemplated hereby, do not and will not: (a) violate or conflict with the certificate of incorporation, by-laws
or other organizational documents of the Company; (b) violate or conflict with any judgment, order, decree, statute, law, ordinance,
rule or regulation applicable to the Company or the Purchased Assets; (c) conflict with, or result in (with or without notice
or lapse of time or both) any violation of, or default under, or give rise to a right of termination, acceleration or modification
of any obligation or loss of any benefit under any Assigned Contracts or (d) result in the creation or imposition of any Encumbrance
on the Purchased Assets. Except as set forth in Section 3.02 of the Disclosure Schedules, no consent, approval, waiver
or authorization is required to be obtained by the Company from any person or entity (including any governmental authority) in
connection with the execution, delivery and performance by the Company of this Agreement and the consummation of the transactions
contemplated hereby.

 

Section
3.03 Title to Purchased Assets. Except as set forth in Section 3.03 of the Disclosure Schedules, the Company owns and
has good title to the Purchased Assets, free and clear of Encumbrances.

 

Section
3.04 Inventory. Section 3.04 of the Disclosure Schedules sets forth a true and complete list of the quantity of Inventory,
and such Inventory consists of a quality that is usable and salable in the ordinary course of business.

 

Section
3.05 Intellectual Property.

 

(a)
Except as set forth in Schedule 3.05(a), the Company owns or has adequate, valid and enforceable rights to use all of the
Purchased IP, free and clear of all Encumbrances. The Company is not bound by any outstanding judgment, injunction, order or decree
restricting the use of the Purchased IP, or restricting the licensing thereof to any person or entity.

 

(b)
To the Company’s knowledge, (i) its use of the Purchased IP does not infringe, violate, dilute or misappropriate the intellectual
property of any other person or entity and (ii) there are no claims pending or threatened by any person or entity with respect
to the ownership, validity, enforceability, effectiveness or use of the Purchased IP. To the Company’s knowledge, no person
or entity is infringing, misappropriating, diluting or otherwise violating any of the Purchased IP, and the Company has not made
or asserted any claim, demand or notice against any person or entity alleging any such infringement, misappropriation, dilution
or other violation.

 

    	 	6	 

    	 

    

 

Section
3.06 Assigned Contracts; [***]. Each Assigned Contract and the [***] is valid and binding on the Company in accordance with
its terms and is in full force and effect. None of the Company or, to the Company’s knowledge, any other party thereto is
in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any
intention to terminate, any Assigned Contract or the [***]. No event or circumstance has occurred that, with or without notice
or lapse of time or both, would constitute an event of default under any Assigned Contract or the [***], or result in a termination
thereof, or would cause or permit the acceleration or other changes of any right or obligation or the loss of benefit thereunder.
Complete and correct copies of each Assigned Contract and the [***] have been made available to Buyer. There are no disputes pending
or, to the Company’s knowledge, threatened under any Assigned Contract or the [***].

 

Section
3.07 Compliance With Laws. The Company is in compliance, in all material respects, with all applicable federal, state and
local laws and regulations applicable to ownership and use of the Purchased Assets.

 

Section
3.08 Legal Proceedings. There is no claim, action, suit, proceeding or governmental investigation (“Action”)
of any nature pending or, to the Company’s knowledge, threatened against or by the Company (a) relating to or affecting
the Purchased Assets or the Assumed Liabilities; or (b) that challenges or seeks to prevent, enjoin or otherwise delay the transactions
contemplated by this Agreement. To the Company’s knowledge, no event has occurred or circumstances exist that may give rise
to, or serve as a basis for, any such Action.

 

Section
3.09 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of the Company.

 

Section
3.10 Taxes. Except as set forth in Section 3.10 of the Disclosure Schedules:

 

(a)
Except as would not have a material adverse effect on the Purchased Assets, the Company has filed (taking into account any valid
extensions) all material tax returns required to be filed by the Company and has paid all taxes shown thereon as owing. The Company
is not currently the beneficiary of any extension of time within to file any material tax return other than extensions of time
to file tax returns obtained in the ordinary course of business.

 

(b)
The Company is not a “foreign person” as that term is used in Treasury Regulations Section 1.1445-2. The Company is
not, nor or has been, a United States real property holding corporation (as defined in Section 897(c)(2) of the Code) during the
applicable period specified in Section 897(c)(1)(a) of the Code.

 

(c)
The representations and warranties set forth in this Section 3.10 are the Company’s sole and exclusive representations
and warranties regarding tax matters.

 

Section
3.11 Full Disclosure. No representation or warranty by the Company in this Agreement and no statement contained in the Disclosure
Schedules to this Agreement or any certificate or other document furnished or to be furnished to Buyer pursuant to this Agreement
contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements contained
therein, in light of the circumstances in which they are made, not misleading.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 	7	 

    	 

    

 

Article
IV

REPRESENTATIONS AND WARRANTIES OF BUYER

 

Buyer
represents and warrants to the Company that the statements contained in this Article IV are true and correct as of the
date hereof. For purposes of this Article IV, “Buyer’s knowledge,” “knowledge of Buyer” and
any similar phrases shall mean the actual or constructive knowledge of any officer of Buyer, after reasonable inquiry.

 

Section
4.01 Organization and Authority of Buyer; Enforceability. Buyer is a corporation duly organized, validly existing and in good
standing under the laws of the state of Delaware. Buyer has full corporate power and authority to enter into this Agreement and
the documents to be delivered by Buyer hereunder, to carry out its obligations hereunder and to consummate the transactions contemplated
hereby. The execution, delivery and performance by Buyer of this Agreement and the documents to be delivered by Buyer hereunder
and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the
part of Buyer. This Agreement and the documents to be delivered by Buyer hereunder have been duly executed and delivered by Buyer,
and (assuming due authorization, execution and delivery by the Company) this Agreement and the documents to be delivered hereunder
constitute legal, valid and binding obligations of Buyer enforceable against Buyer in accordance with their respective terms.

 

Section
4.02 No Conflicts; Consents. The execution, delivery and performance by Buyer of this Agreement and the documents to be delivered
by Buyer hereunder, and the consummation of the transactions contemplated hereby, do not and will not: (a) violate or conflict
with the certificate of incorporation, by-laws or other organizational documents of Buyer; or (b) violate or conflict with any
judgment, order, decree, statute, law, ordinance, rule or regulation applicable to Buyer. No consent, approval, waiver or authorization
is required to be obtained by Buyer from any person or entity (including any governmental authority) in connection with the execution,
delivery and performance by Buyer of this Agreement and the consummation of the transactions contemplated hereby.

 

Section
4.03 Legal Proceedings. There is no Action of any nature pending or, to Buyer’s knowledge, threatened against or by
Buyer that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. To Buyer’s
knowledge, no event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action.

 

Section
4.04 Brokers. No broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Buyer.

 

    	 	8	 

    	 

    

 

Article
V

COVENANTS

 

Section
5.01 Option to Unwind. This Agreement, and the transactions contemplated hereby, have been entered into in anticipation of
a merger by [***] and wholly owned subsidiary of [***] (“Bio IVT”), with and into the Company, pursuant to
which the Company will survive as a wholly owned subsidiary of Bio IVT (the “Merger”). If the Merger is not
consummated within 90 days after the Closing Date (the “Merger Deadline”), then the Company may elect to unwind
the transactions contemplated by this Agreement. In the event the Company elects to unwind the transactions contemplated by this
Agreement, the Company shall provide written notice of such election to Buyer within 15 days after the Merger Deadline. Following
delivery of such notice, the parties hereto shall cooperate in good faith to promptly (but in any event within 10 days after delivery
of such notice) unwind the transactions contemplated hereby, including by returning the Purchased Assets and Assumed Liabilities,
or Purchase Price, as applicable, to the other party.

 

Section
5.02 Public Announcements. Except for disclosures in compliance with federal and state securities laws and the rules and regulations
thereunder, and the rules of the national securities exchange on which securities of Buyer’s parent corporation are traded,
and unless otherwise required by applicable law, neither party hereto shall make any public announcements regarding this Agreement
or the transactions contemplated hereby without the prior written consent of the other party (which consent shall not be unreasonably
withheld or delayed).

 

Section
5.03 Bulk Sales Laws. The parties hereby waive compliance with the provisions of any bulk sales, bulk transfer or similar
laws of any jurisdiction that may otherwise be applicable with respect to the sale of any or all of the Purchased Assets to Buyer.

 

Section
5.04 Transfer Taxes. All transfer, documentary, sales, use, stamp, registration, value added and other such taxes and fees
(including any penalties and interest) incurred in connection with this Agreement and the documents to be delivered hereunder
shall be borne and paid 50% by Buyer and 50% by the Company. The parties hereto shall cooperate, and use commercially reasonable
efforts, to timely file any tax return or other document with respect to such taxes or fees.

 

Section
5.05 Further Assurances. Following the Closing, each of the parties hereto shall execute and deliver such additional documents,
instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions
hereof and give effect to the transactions contemplated by this Agreement and the documents to be delivered hereunder.

 

Article
VI

INDEMNIFICATION

 

Section
6.01 Survival. All representations and warranties contained herein and all related rights to indemnification shall survive
for six (6) months after Closing.

  

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 	9	 

    	 

    

 

Section
6.02 Indemnification by the Company. Subject to the other terms and conditions of this Article VI, the Company shall
defend, indemnify and hold harmless Buyer, its affiliates and their respective stockholders, directors, officers and employees
from and against all claims, judgments, damages, liabilities, settlements, losses, costs and expenses, including reasonable attorneys’
fees and disbursements, arising from or relating to:

 

(a)
any inaccuracy in or breach of any of the representations or warranties of the Company contained in this Agreement or any document
to be delivered hereunder;

 

(b)
any breach or non-fulfillment of any covenant, agreement or obligation to be performed by the Company pursuant to this Agreement
or any document to be delivered hereunder;

 

(c)
any Excluded Asset; or

 

(d)
Retained Liabilities.

 

Section
6.03 Indemnification by Buyer. Subject to the other terms and conditions of this Article VI, Buyer shall defend, indemnify
and hold harmless the Company, its affiliates and their respective stockholders, directors, officers and employees from and against
all claims, judgments, damages, liabilities, settlements, losses, costs and expenses, including reasonable attorneys’ fees
and disbursements, arising from or relating to:

 

(a)
any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement or any document to
be delivered hereunder;

 

(b)
any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement or
any document to be delivered hereunder; or

 

(c)
any Assumed Liability.

 

Section
6.04 Certain Limitations. The party making a claim under this Article VI is referred to as the “Indemnified
Party”, and the party against whom such claim is asserted under this Article VI is referred to as the “Indemnifying
Party”. The indemnification provided for in this Article VI shall be subject to the following limitations:

 

(a)
The aggregate amount of all losses for which an Indemnifying Party shall be liable pursuant to this Article VI shall not
exceed $[***].

 

(b)
In no event shall any Indemnifying Party be liable to any Indemnified Party for any punitive, incidental, consequential, special
or indirect damages, including loss of future revenue or income, loss of business reputation or opportunity relating to the breach
or alleged breach of this Agreement, or diminution of value or any damages based on any type of multiple.

 

(c)
Payments by an Indemnifying Party pursuant to this Article VI in respect of any loss shall be limited to the amount of
any liability or damage that remains after deducting therefrom any insurance proceeds and any indemnity, contribution or other
similar payment received or reasonably expected to be received by the Indemnified Party in respect of any such claim. The Indemnified
Party shall use its commercially reasonable efforts to recover under insurance policies or indemnity, contribution or other similar
agreements for any losses prior to seeking indemnification under this Agreement.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 	10	 

    	 

    

 

(d)
Each Indemnified Party shall take, and cause its affiliates to take, all reasonable steps to mitigate any loss upon becoming aware
of any event or circumstance that would be reasonably expected to, or does, give rise thereto, including incurring costs only
to the minimum extent necessary to remedy the breach that gives rise to such loss.

 

Section
6.05 Indemnification Procedures. Whenever any claim shall arise for indemnification hereunder, the Indemnified Party shall
promptly provide written notice of such claim to the Indemnifying Party (the “Claim Notice”); provided, that
no delay in so notifying the Indemnifying Party shall relieve the Indemnifying Party of any of its obligations under this Article
VI except to the extent that such delay results in a loss or impairment of procedural or substantive rights with respect to
the defense of the claim. In connection with any claim giving rise to indemnity hereunder resulting from or arising out of any
Action by a person or entity who is not a party to this Agreement, the Indemnifying Party, at its sole cost and expense and upon
written notice to the Indemnified Party, shall assume the defense of any such Action with counsel reasonably satisfactory to the
Indemnified Party. The Indemnified Party shall be entitled to participate in the defense of any such Action, with its counsel
and at its own cost and expense; provided, however, that if both the Indemnifying Party and Indemnified Party are parties to the
Action, and if any conflict of interest (including, but not limited to, crossclaims between them) arises between them or different
defenses become available to them, the cost of such separate counsel (but not more than one separate law firm) for the Indemnified
Party shall be borne by the Indemnifying Party. If the Indemnifying Party does not assume the defense of any such Action within
twenty (20) days after the Claim Notice or such earlier time as may be required to file an answer or other response in the Action
so as to avoid a default or loss of any material procedural or substantive rights, the Indemnified Party may, but shall not be
obligated to, defend against such Action, at the Indemnifying Party’s expense, in such manner as it may deem appropriate,
including, but not limited to, settling such Action, after giving notice of it to the Indemnifying Party, on such terms as the
Indemnified Party may deem appropriate and no action taken by the Indemnified Party in accordance with such defense and settlement
shall relieve the Indemnifying Party of its indemnification obligations herein provided with respect to any damages resulting
therefrom. The Indemnifying Party shall not settle any Action without the Indemnified Party’s prior written consent (which
consent shall not be unreasonably withheld or delayed).

 

Section
6.06 Tax Treatment of Indemnification Payments. All indemnification payments made under this Agreement shall be treated by
the parties hereto as an adjustment to the Purchase Price for tax purposes, unless otherwise required by law.

 

Section
6.07 Exclusive Remedies. The parties acknowledge and agree that their sole and exclusive remedy with respect to any and all
claims (other than claims arising from intentional fraud on the part of a party hereto in connection with the transactions contemplated
by this Agreement) for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise
relating to the subject matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this Article
VI.

 

    	 	11	 

    	 

    

 

Article
VII

MISCELLANEOUS

 

Section
7.01 Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby
shall be paid by the party incurring such costs and expenses.

 

Section
7.02 Interpretation. Whenever the words “include,” “includes” or “including” are used
in this Agreement, they shall be deemed to be followed by the words “without limitation.” Words denoting any gender
shall include all genders. Where a word is defined herein, references to the singular shall include references to the plural and
vice versa. A reference to any party to this Agreement or any other agreement or document shall include such party’s successors
and permitted assigns. All references to “$” and dollars shall be deemed to refer to United States currency unless
otherwise specifically provided. All references to a day or days shall be deemed to refer to a calendar day or calendar days,
as applicable, unless otherwise specifically provided. Any reference to any agreement or contract referenced herein or in the
Disclosure Schedules shall be a reference to such agreement or contract, as amended, modified, supplemented or waived. The captions
used in this Agreement and descriptions of the Disclosure Schedules are for convenience of reference only and do not constitute
a part of this Agreement and shall not be deemed to limit, characterize or in any way affect any provision of this Agreement,
and all provisions of this Agreement shall be enforced and construed as if no caption or description of the Disclosure Schedules
had been used in this Agreement. The phrase “made available to Buyer” or similar phrases as used in this Agreement
shall mean that the subject documents were posted to the virtual data room hosted by Merrill Corporation and maintained by the
Company or its representatives prior to the date hereof. Unless otherwise specified herein, references to any statute, listing
rule, rule, standard, regulation or other law include a reference to the corresponding rules and regulations and each of them
as amended, modified, supplemented, consolidated, replaced or rewritten from time to time. References to any section of any statute,
listing rule, rule, standard, regulation or other law include any successor to such section.

 

Section
7.03 Notices. All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing
and shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by
the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or e-mail
of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business
day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered
mail, return receipt requested, postage prepaid. Such communications must be sent to the respective parties at the following addresses
(or at such other address for a party as shall be specified in a notice given in accordance with this Section 7.03):

 

	If
    to the Company:	Ascendance
                                         Biotechnology, Inc.

        200
        Boston Avenue, Suite 1500

        Medford,
        MA 02155

        Attention:
        Vincent R. Zurawski, Jr., Ph.D.

        Email:
        vzurawski@ascendancebio.com

 

    	 	12	 

    	 

    

 

	with
    a copy to:	Duane
                                         Morris LLP

        30
        South 17th Street

        Philadelphia,
        PA 19103

        Facsimile:
        (215) 689-4452

        E-mail:
        toner@duanemorris.com

        Attention:
        David Toner, Esq.

	 	 
	If
    to Buyer:	AgeX
                                         Therapeutics, Inc.

        1010
        Atlantic Avenue

        Alameda,
        California 94501

        Facsimile:
        (510) 521-3389

        E-mail:
        mwest@biotimeinc.com

        Attention:
        Michael D. West, CEO

        

	 	 
	with
    a copy to:	Thompson,
                                         Welch, Soroko &Gilbert LLP

        450
        Pacific Avenue, Suite 200

        San
        Francisco, CA 91433

        Attention:
        Richard S. Soroko

 

Section
7.04 Headings. The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

Section
7.05 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable
law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder
of such provisions or the remaining provisions of this Agreement.

 

Section
7.06 Entire Agreement. This Agreement and the documents to be delivered hereunder constitute the sole and entire agreement
of the parties to this Agreement with respect to the subject matter contained herein, and supersede all prior and contemporaneous
understandings and agreements, both written and oral, with respect to such subject matter. In the event of any inconsistency between
the statements in the body of this Agreement and the other documents to be delivered hereunder (other than an exception set forth
in the Disclosure Schedules), the statements in the body of this Agreement will control.

 

Section
7.07 Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and
their respective successors and permitted assigns. Neither party may assign its rights or obligations hereunder without the prior
written consent of the other party, which consent shall not be unreasonably withheld or delayed. No assignment shall relieve the
assigning party of any of its obligations hereunder.

 

Section
7.08 No Third-party Beneficiaries. Except as provided in Article VI, this Agreement is for the sole benefit of the
parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or
shall confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or
by reason of this Agreement.

 

    	 	13	 

    	 

    

 

Section
7.09 Amendment and Modification. This Agreement may only be amended, modified or supplemented by an agreement in writing signed
by each party hereto.

 

Section
7.10 Waiver. No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing
and signed by the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure,
breach or default not expressly identified by such written waiver, whether of a similar or different character, and whether occurring
before or after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from
this Agreement shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy,
power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power
or privilege.

 

Section
7.11 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of
Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other
jurisdiction).

 

Section
7.12 Submission to Jurisdiction. This Agreement has been executed and delivered in and shall be deemed to have been made in
the State of Delaware. The parties each agree to the exclusive jurisdiction of the Chancery Court of the State of Delaware (or,
if the Chancery Court of the State of Delaware declines to accept jurisdiction over a particular matter, any state or federal
court sitting in the State of Delaware), with respect to any Claim arising under or relating to this Agreement and/or the transactions
contemplated hereunder, and waives personal service of any and all process upon it, and consents that all services of process
be made by registered or certified mail, return receipt requested, directed to it at its address as set forth in Section 7.03,
and service so made shall be deemed to be completed when received. The parties each waive any objection based on forum non conveniens
and waive any objection to venue of any action instituted hereunder. Nothing in this paragraph shall affect the right of the parties
to serve legal process in any other manner permitted by law.

 

Section
7.13 Waiver of Jury Trial. Each party acknowledges and agrees that any controversy which may arise under this Agreement is
likely to involve complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any
right it may have to a trial by jury in respect of any legal action arising out of or relating to this Agreement or the transactions
contemplated hereby.

 

Section
7.14 Specific Performance. The parties hereto agree that irreparable damage would occur if any provision of this Agreement
were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms
hereof, in addition to any other remedy to which they are entitled at law or in equity.

 

Section
7.15 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which
together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other
means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this
Agreement.

 

Section
7.16 Wrong Pockets. From time to time following the Closing, and for no further consideration, Buyer and the Company shall
(or shall cause their respective affiliates to) execute, acknowledge and deliver such assignments, transfers, consents, assumptions,
conveyances and other documents and instruments and take such other actions as may reasonably be necessary to appropriately consummate
the transactions contemplated hereby, including (a) transferring back to the Company (or its designee), at no additional cost
to the Company (or its designee), any right, property, asset or liability that was not contemplated by this Agreement to be transferred
to or assumed by Buyer but is found to have been transferred to or assumed by Buyer in error, either directly or indirectly and
(b) transferring to Buyer (or its designee), at no additional cost to Buyer (or its designee), any right, property, asset or liability
that was contemplated by this Agreement to be transferred to or assumed by Buyer at or after the Closing but is found to not have
been so transferred to or assumed by Buyer.

 

[Signature
Page Follows]

 

    	 	14	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first written above by their respective
officers thereunto duly authorized.

 

	 	ASCENDANCE
    BIOTECHNOLOGY, INC.  
	 	 
	 	By:	/s/
    Vincent R. Zurawski, Jr.
	 	Name:	Vincent
    R. Zurawski, Jr., Ph.D.
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	AGEX
    THERAPEUTICS, INC.
	 	 	 
	 	By:	/s/
    Michael D. West 
	 	Name:	Michael
    D. West
	 	Title:	Chief
    Executive Officer

 

[Signature
Page to Asset Purchase Agreement]

 

    	 	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]